The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects
about
From ARB to ARNI in Cardiovascular ControlDementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects.Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure.Potential Expanded Indications for Neprilysin Inhibitors.Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the USA.Long-term neprilysin inhibition - implications for ARNIs.Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis.Response by Hubers and Brown to Letter Regarding Article, "Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition".Angiotensin Receptor-Neprilysin Inhibition.Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension.How publication guidelines for clinical pharmacology trials may help to accelerate knowledge transfer.Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.[The new ESC Guidelines for acute and chronic heart failure 2016].Sacubitril/Valsartan (LCZ696) in Heart FailureA New Approach for Hypertension: the Case of Sacubitril/Valsartan Experienced in Randomized Controlled Trials That Selectively Restrict Its Use to the Hypertension of the ElderlyMetabolic effects of sacubitril/valsartan: are they relevant in clinical practice?Sacubitril/valsartan: a cardiovascular drug with pluripotential actions
P2860
Q28073372-91397417-96AB-4D1C-9D51-9F1F134020D2Q37595978-1082687A-7E41-4C1B-92C0-5DF5B89C9C5EQ38685645-2F7FCF7B-48E5-4926-9187-2652091EB853Q38737757-378CAD4B-298A-4F4E-B4CF-27B41E37F740Q38747742-57EBD81A-77F3-4760-98FA-26386DCF313AQ38750210-9553117F-8E13-4899-943B-4859DC8579F3Q38924076-26D763D7-A138-4A1E-9CC2-B62B1633D721Q39038686-94E31798-43F6-4DE0-AEDD-CE5A1CDC7BB0Q39247505-0FC18949-052B-4AB0-8223-4EBDAD3FD74BQ39641551-FC315A7E-C9F8-426D-84BB-0030AA680C13Q42407960-F3CD4FE3-3A7C-43FD-B276-494685D0D0FBQ46770238-844EE9B3-AE25-45CB-A46C-4BBCEC84E415Q48234735-58DA6095-AB6C-4C57-83EE-F509D0E95FE5Q50088331-81F8B334-376A-4A7A-9E1D-4C2E21323EACQ50634411-F32C80AA-F372-489C-87A3-E1E4B46C7EBBQ52844963-519BBCEA-0CB1-4DBC-9144-49A37A26EB40Q57396137-DD459CD5-0DE2-48A7-81B6-0869BB954210Q57787813-A4210073-278E-45C6-9B2A-3CEC8801CB5BQ58804503-97964266-652F-4043-B591-F4C92BF6F994Q58804507-1B305D01-ECCE-48CC-B82D-FB4C385101A6
P2860
The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The effect of LCZ696 (sacubitr ...... inal fluid in healthy subjects
@ast
The effect of LCZ696 (sacubitr ...... inal fluid in healthy subjects
@en
type
label
The effect of LCZ696 (sacubitr ...... inal fluid in healthy subjects
@ast
The effect of LCZ696 (sacubitr ...... inal fluid in healthy subjects
@en
prefLabel
The effect of LCZ696 (sacubitr ...... inal fluid in healthy subjects
@ast
The effect of LCZ696 (sacubitr ...... inal fluid in healthy subjects
@en
P2093
P2860
P356
P1476
The effect of LCZ696 (sacubitr ...... inal fluid in healthy subjects
@en
P2093
Chiaki Tsubouchi
Hakop Gevorkyan
Iris Rajman
Marie-Anne Valentin
Markus Hinder
Parasar Pal
Stanford Jhee
Thomas H Langenickel
P2860
P304
P356
10.1111/BCP.12861
P407
P577
2015-12-12T00:00:00Z